Chinese guideline for lipid management(2023):a new guideline rich in domestic elements for controlling dyslipidemia

作     者：Jian-Jun LI Jian-Jun LI

作者机构：Division of Cardio-Metabolic CenterState Key Laboratory of Cardiovascular DiseaseFu Wai HospitalNational Center for Cardiovascular DiseaseChinese Academy of Medical SciencesPeking Union Medical CollegeBeijingChina 

出 版 物：《老年心脏病学杂志:英文版》 (Journal of Geriatric Cardiology)

年 卷 期：2023年第20卷第9期

页      面：618-620页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：CAMS Major Collaborative Innovation Project(2016-I2M-1-011) 

主　　题：elevated simultaneous guideline 

摘      要：Atherosclerotic cardiovascular disease(ASCVD)is the leading cause of death among urban and rural residents in China,and elevated low-density lipoprotein cholesterol(LDL-C)is a causal risk factor for ASCVD.[1,2]Considering the increasing burden of ASCVD,lipid management is of the utmost *** 7 years interval,Chinese guideline for lipid management(2023)(lipid guideline 2023)has simultaneously been published in both Chinese Journal of Cardiology,Chinese Circulation Journal in Chinese language and Frontiers in Pharmacology in English,which has widely been acclaiming at home and abroad.